Breast Cancer Management during the COVID-19 Pandemic: A Review of the Dynamic and Evolving Guidelines and Some Personal Thoughts
Rayan Daoud, Rebecca Badawi, Romy Younan and Georges El Hachem
Journal Title:Acta Scientific Cancer Biology
Nearly, every country around the world is being challenged in every direction by the lethal infectious disease known as COVID-19. The COVID-19 viral pandemic accountable for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease has drasti-cally influenced our work worldwide in the management of patients in terms of diagnosis and surgical treatment of cancer - including breast cancer. In fact, oncology practice has been transformed in response to this crisis. Today, more than ever, oncologists are post-poning chemotherapies, delaying curative surgeries and switching intravenous to oral therapies. This is due to the fact that cancer patients are at a significantly higher risk of getting infected with COVID-19 since their immune system can be compromised. The reality has to do with both that they have cancer and that they are on therapy for their cancer. As medical oncologists, it is our duty to make sure that these cancer patients are treated appropriately with a minimal exposure risk to this crushing virus. Herein, we are presenting a review that introduces the evolving guidelines for management of breast cancer patients in view of this pandemic, along with various methods of risk classifications. We also sought to include a personal analysis and hypothesis for the best optimal oral treatment in a particular bundle of breast cancer patients.